Últimas noticias sobre Merck & Co (NYSE:MRK) Bolsa

Merck & Co

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck & Co Inc

Marker Therapeutics Inc

MARKY CORP by MARKY CORP.

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

Merck Disclosed Closing Of Exclusive Global License Agreement For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody From LaNova Medicine; Company To Record Pre-tax Charge Relating To Upfront Payment Of $588M, Or $0.18 Per Share, In Q4 2024 GAAP And Non-GAAP Results

BMO Capital analyst Evan David Seigerman downgrades Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Outperform to Market Perform and lowers the price target from $136 to $105.

Downgrades

Price Target

BMO Capital Downgrades Merck & Co to Market Perform, Lowers Price Target to $105

On Thursday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42572326/merck-announces-topline-results-from-pivotal-phase-3-trials-evaluating-investigational-once-daily-" rel="noreferrer noopener">with HIV-1 infection</a>.
The trials included patients who were virologically suppressed on different antiretroviral therapy regimens, including antiretroviral therapy regimens [baseline antiretroviral therapy (<a target="_blank" href="https://clinicaltrials.gov/study/NCT05631093" rel="noreferrer noopener">bART</a>) and Bictegravir/​Emtricitabine/​Tenofovir Alafenamide (<a target="_blank" href="https://clinicaltrials.gov/study/NCT05630755" rel="noreferrer noopener">BIC/​FTC/​TAF</a>).
DOR/ISL was demonstrated to be non-inferior to bART in open-label trial MK-8591A-051 and non-inferior to BIC/FTC/TAF in double-blind trial MK-8591A-052.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41434127/gilead-sciencesmercks-investigational-once-weekly-hiv-combo-therapy-shows-sustained-virus-suppres" rel="noreferrer noopener">Gilead Sciences/Merck&#8217;s Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks</a>
Trial MK-8591A-052 did not meet the superiority criteria, but both trials also met the primary safety objectives.
The company plans to present detailed findings from these trials at a future scientific congress and file the data with regulatory authorities.
In the U.S., doravirine is approved for the treatment of adults with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a component of a single-tablet regimen [DELSTRIGO; doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF)].
Islatravir (MK-8591), Merck&#8217;s investigational drug, is being evaluated in multiple early and late-stage clinical trials in combination with other antiretroviral therapies for the treatment of HIV-1.
In addition to the MK-8591A-051 and MK-8591A-052 trials, ongoing Phase 3 trials of DOR/ISL include&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05705349&amp;esheet=54169231&amp;newsitemid=20241219661570&amp;lan=en-US&amp;anchor=MK-8591A-053&amp;index=3&amp;md5=289fad4b8e112f0df5a7c56584cbba83" rel="noreferrer noopener">MK-8591A-053</a> in people with HIV who had not previously received treatment (treatment-naïve) and&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05766501%3Fterm%3Dislatravir%26page%3D2%26rank%3D12&amp;esheet=54169231&amp;newsitemid=20241219661570&amp;lan=en-US&amp;anchor=MK-8591A-054&amp;index=4&amp;md5=93a25503967ab506b3a49091d73d2bc9" rel="noreferrer noopener">MK-8591A-054</a> evaluating open-label DOR/ISL in individuals who participated in earlier Phase 3 trials of DOR/ISL.
Price Action: MRK stock is up 1.18% at $99.50 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42598735/nip-group-to-see-14-revenue-growth-in-2025-analyst-projects-solid-long-term-growth" target="_blank" rel="noreferrer noopener">From Anime To Abu Dhabi: Analyst Sees NIP Group Transforming Entertainment And Tech</a></li>
</ul>
Photo: HIV/AIDS ribbon via Shutterstock.

Equities

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Government

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

Shares of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) are trading flat on Thursday, but remain in a downtrend.
If the stock eventually reaches levels around $95.00, there is a good chance it reverses and heads higher. As you can see on the chart, this is what happened in late November. This is why our technical analysis team has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png" alt="Merck" class="wp-image-700197" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14.png 1491w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
There has been a lot of news coming from Merck.
The advanced cancer genomic testing provider Personalis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) said it received a $50 million equity investment from Merck.&nbsp; When the deal closes, Merck will own 16.5% of Personalis.
Merck also announced that <a href="https://www.benzinga.com/24/12/42554599/whats-going-on-with-merck-shares-wednesday">it is entering the lucrative obesity market</a>. It is licensing rights from Chinese biotech Hansoh Pharmaceutical Group Company Limited&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNSPF#OTC">HNSPF</a>)to an investigational oral GLP – 1 receptor.
The chart of Merck offers some simple but valuable technical analysis lessons. Price levels that had been resistance can convert into support. Also, stocks that drop to support have a tendency to rally.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases">Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases</a>
$119.40 was resistance in May 2023. Some of the investors who sold then were happy when the price fell soon after. They thought they made a good decision.
But in January 2024 the resistance broke and the stock moved higher. When this happened, some of these sellers came to think they made a mistake and decided to buy their shares back if they can do so at the same price they sold them for.
So, when the stock dropped back to around $119.40 in March 2024 they placed buy orders. The large concentration of these orders formed support at the same price that had been resistance.
Similar action occurred at the $111.00 level. It was resistance in August 2023. Then it became support a year later in August 2024.
In July 2022, the $95.00 level was resistance. It converted into support last month, and it may be support again if Merck reaches it.
As you can also see on the chart, sometimes stocks rally after they reach support. This happens when some of the buyers who created the support think they will get outbid. If someone else is willing to pay a higher price, that's who the sellers will go to.
As a result, they increase the prices they are willing to pay. Others see this and do the same. It can cause a snowball effect that pushes the stock higher and it may be about to happen with Merck.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42595485/bitcoin-rebounds-above-102000-post-fed-meeting-us-gdp-hits-31-jobless-claims-drop-treasury-yields-peak-teslas-eu-registrations-fall-41-q4-ev-target-in-doubt-top-headlines-today-while-us-slept">Bitcoin Rebounds Above $102,000 Post-Fed Meeting; Us GDP Hits 3.1%, Jobless Claims Drop, Treasury Yields Peak &#8211; Top Headlines Today While US Slept</a></li>
</ul>
Image: Courtesy of Merck.

Technicals

HNSPF

PSNL

Stock Of The Day: Where Does The Merck Downtrend End?

Merck Agrees To Purchase $50M Of Personalis Common Stock In A Private Placement At A Price Of $3.56 Per Share

Merck Announced Topline Results From Two Phase 3 Trials Of Doravirine/Islatravir In Adults With HIV-1 Infection That Is Virologically Suppressed On Different Antiretroviral Therapy Regimens, Trials Met Efficacy Success Criteria For Non-inferiority To Comparator Antiretroviral Therapies

Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and <a href="https://www.benzinga.com/24/12/42531132/why-are-teva-and-sanofi-stocks-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Crohn&#8217;s disease (CD)</a>.
In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission compared to 20.45% on placebo, placebo-adjusted rates were 15.7% (low dose) and 27.4% (high dose), at week 14.
BofA Securities raised the price target for Teva to $25 from $23 <a target="_blank" href="https://www.benzinga.com/quote/TEVA/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>, reflecting a strong Phase 2 data update for duvakitug in inflammatory bowel disorders (IBD).
Based on the strength of the data and the emerging product prole, the analyst forecasts nominal peak sales of ~$2 billion (booked by partner), with Teva booking half the profits.
Given the anticipated impact on profits by 2030, BofA factors in the long-term strength of Teva&#8217;s innovative portfolio by applying a valuation multiple of 9.25x to 2025 estimated EV/EBITDA.
Partnership milestone payments provide reliable cash flow, and the analyst sees potential for the stock to gain value as the company shifts toward growth-focused execution.
The TL1a drug class has emerged over the last two years, led by Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Prometheus&#8217; strong Phase 2 data, which was followed by similar data from Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) competitor asset.
BofA writes that TL1a was a class of drug that could offer a very good safety profile, on par with market-leading Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) Entyvio, plus a high rate of efficacy across all major patient subgroups.
Data update from Teva in around 240 patients in Phase 2 showed 16%-27% placebo-adjusted MAYO remission scores in the UC population, with the high dose compared favorably to competitors.
TEVA Price Action: Teva Pharmaceutical stock is up 3.23% at $21.56 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42557565/ozempic-maker-novo-nordisks-poised-to-go-under-european-review-for-potential-increased-risk-of-rare-eye-disease" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease</a></li>
</ul>
Photo: Courtey Teva Pharmaceutical Industries

Movers

RHHBY

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

On Wednesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42549621/merck-enters-into-exclusive-global-license-agreement-with-hansoh-pharma-for-investigational-oral-g" rel="noreferrer noopener">molecule GLP-1 receptor agonist</a>.
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the candidate&#8217;s development, regulatory approval, and commercialization, as well as royalties on sales.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42096338/viking-therapeutics-garners-analyst-support-for-nash-and-metabolic-programs" rel="noreferrer noopener">Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs</a>
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.
William Blair writes that Merck is seen as a strong candidate to acquire Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), leading to an expected sell-off in Viking shares. However, the analyst notes that the licensing agreement with Hansoh will not hinder Merck from pursuing additional external business development opportunities in the obesity space.
The licensing deal highlights Merck&#8217;s commitment to obesity, potentially driving further growth through additional partnerships. While the focus on Viking increases investment volatility, data from competitors or new licensing deals could significantly affect its stock.
William Blair remains confident that Viking offers a valuable asset with VK2735, a GLP-1/GIP dual agonist that could become a major player in obesity treatment due to its potential for monthly maintenance <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" rel="noreferrer noopener">dosing and oral formulation options</a>.
This asset could strengthen an acquiring company&#8217;s obesity portfolio, with additional potential from Viking&#8217;s amylin program.
Overall, the analyst is optimistic about Viking&#8217;s prospects, maintaining the stock as a top pick for 2025 and an Outperform <a target="_blank" href="https://www.benzinga.com/quote/VKTX/analyst-ratings" rel="noreferrer noopener">rating on its shares</a>.
Price Action: VKTX stock is down 11.4% at $41.37 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42559199/renewable-energy-company-orsted-sells-50-stake-in-us-solar-and-battery-projects-for-572m" target="_blank" rel="noreferrer noopener">Renewable Energy Company Ørsted Sells 50% Stake In US Solar And Battery Projects For $572 Million: Details</a></li>
</ul>
Photo via Shutterstock.

Contracts

Reiteration

VKTX

What's Going On With Viking Therapeutics Stock On Wednesday?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRDF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$56.3K</td>
<td>1.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$500.00</td>
<td>$51.9K</td>
<td>2.4K</td>
<td>687</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$32.00</td>
<td>$34.4K</td>
<td>2.0K</td>
<td>648</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$37.00</td>
<td>$47.5K</td>
<td>1.8K</td>
<td>321</td>
</tr>
<tr>
<td>PEN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$280.00</td>
<td>$52.2K</td>
<td>0</td>
<td>223</td>
</tr>
<tr>
<td>NMRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$36.0K</td>
<td>13.7K</td>
<td>104</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$90.00</td>
<td>$25.0K</td>
<td>3.6K</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$97.00</td>
<td>$25.8K</td>
<td>28</td>
<td>46</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$290.00</td>
<td>$29.8K</td>
<td>26</td>
<td>42</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$780.00</td>
<td>$127.8K</td>
<td>238</td>
<td>27</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding CRDF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>), we observe a call option sweep with bullish sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 663 contract(s) at a $5.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $56.3K, with a price of $88.0 per contract. There were 1040 open contracts at this strike prior to today, and today 1104 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option sweep that happens to be neutral, expiring in 30 day(s) on January 17, 2025. This event was a transfer of 21 contract(s) at a $500.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $51.9K, with a price of $2480.0 per contract. There were 2415 open contracts at this strike prior to today, and today 687 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on December 20, 2024. This event was a transfer of 128 contract(s) at a $32.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $34.4K, with a price of $279.0 per contract. There were 2000 open contracts at this strike prior to today, and today 648 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option sweep with bullish sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $37.00 strike. This particular put needed to be split into 41 different trades to become filled. The total cost received by the writing party (or parties) was $47.5K, with a price of $190.0 per contract. There were 1897 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• For PEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), we notice a call option trade that happens to be bullish, expiring in 212 day(s) on July 18, 2025. This event was a transfer of 25 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $52.2K, with a price of $2090.0 per contract. There were 0 open contracts at this strike prior to today, and today 223 contract(s) were bought and sold. 
• Regarding NMRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>), we observe a call option trade with neutral sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $360.0 per contract. There were 13769 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option trade with bullish sentiment. It expires in 394 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 3611 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bearish sentiment. It expires in 2 day(s) on December 20, 2024. Parties traded 22 contract(s) at a $97.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $1175.0 per contract. There were 28 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option sweep that happens to be neutral, expiring in 120 day(s) on April 17, 2025. This event was a transfer of 15 contract(s) at a $290.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $29.8K, with a price of $1990.0 per contract. There were 26 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be neutral, expiring in 184 day(s) on June 20, 2025. This event was a transfer of 18 contract(s) at a $780.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $127.8K, with a price of $7105.0 per contract. There were 238 open contracts at this strike prior to today, and today 27 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

CRDF

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NMRA

10 Health Care Stocks With Whale Alerts In Today's Session

Merck &amp; Company Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) on Wednesday announced a GLP-1 agreement with <a href="https://www.benzinga.com/pressreleases/24/12/b42549621/merck-enters-into-exclusive-global-license-agreement-with-hansoh-pharma-for-investigational-oral-g">Chinese biopharmaceutical company Hansoh Pharma</a>.
What Happened: Merck and Hansoh entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
Hansoh Pharma granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. The Chinese biopharmaceutical company will receive an upfront payment of&nbsp;$112 million and up to&nbsp;$1.9 billion&nbsp;in milestone payments. Hansoh will also receive royalties on sales. 
&#8220;We continue to leverage science-driven business development to augment and complement our robust pipeline,&#8221; said Dean Li, president of Merck Research Laboratories. 
&#8220;Through this agreement, we aim to build on our experience targeting incretin biology to evaluate HS-10535 and its potential to provide additional cardiometabolic benefits beyond weight reduction.&#8221;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42552855/boeing-baker-hughes-wabtec-and-a-financial-stock-on-cnbcs-final-trades">Boeing, Baker Hughes, Wabtec And A Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
As a result of the agreement, Merck said it expects to record a fourth-quarter pre-tax charge of&nbsp;$112 million, or&nbsp;4 cents&nbsp;per share. 
Merck is not due to report its fourth-quarter financial results until February. Analysts currently expect the company to report earnings of $1.83 per share and revenue of $15.43 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
MRK Price Action: <a href="http://benzinga.com/quote/mrk">Merck shares</a> were up 0.83% at $100.89 at the time of writing Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Merck.

Global

What's Going On With Merck Shares Wednesday?

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales.
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.

Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones

On Monday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed that it would discontinue the clinical development programs for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42518399/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs-evaluating-investigatio" rel="noreferrer noopener">vibostolimab and favezelimab</a>.
Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program.
Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program.
Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung cancer (NSCLC), based on the recommendation of an independent Data Monitoring Committee (DMC).
In a pre-planned analysis, both trials met the pre-specified futility criteria for the primary endpoint of overall survival.
As expected with dual checkpoint inhibitor therapy, more immune-related adverse events were observed with the fixed-dose combination than with pembrolizumab.
Considering the totality of data from the Phase 3 KeyVibe studies, including the efficacy outcomes from KeyVibe-003 and KeyVibe-007, the company has decided to discontinue the Phase 3 KeyVibe-006 trial and other vibostolimab studies.
Separately, Merck will end the favezelimab clinical development program and stop enrollment in the Phase 3 KEYFORM-008 trial of a fixed-dose combination of favezelimab and pembrolizumab for relapsed or refractory classical Hodgkin lymphoma (cHL) whose disease has progressed following prior anti-PD-1 therapy.
Patients currently in this trial may continue therapy until the study is completed.
KEYFORM-008 is the only Phase 3 study in the KEYFORM clinical development program for which results are not available.
The company made this decision after a thorough evaluation of data from the favezelimab clinical program and will prioritize the development of other candidates in its comprehensive and diversified oncology pipeline.
This decision is not based on any concerns about the safety of this fixed-dose combination.
On Tuesday, the FDA accepted Merck&#8217;s Biologics License Application (BLA) for clesrovimab (MK-1654), the company&#8217;s investigational prophylactic long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season.
The FDA has set June 10, 2025, as the target action date for the Prescription Drug User Fee Act (PDUFA).
The application is supported by results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) of a single dose of clesrovimab administered to healthy preterm and full-term infants and interim results from the ongoing Phase 3 SMART trial (MK-1654-007) of clesrovimab versus palivizumab in infants and children at increased risk for severe RSV disease.
If approved, Merck anticipates that clesrovimab will be available for physicians and healthcare administrators to order by July 2025, with shipments arriving in time for the 2025 RSV season.
Price Action: MRK stock is up 0.10% at $100.16 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/small-cap/24/12/42534596/wearable-devices-to-debut-neural-controlled-augmented-reality-glasses-at-ces-2025" target="_blank" rel="noreferrer noopener">Wearable Devices To Debut Neural-Controlled Augmented Reality Glasses At CES 2025</a></li>
</ul>

Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis

If approved, clesrovimab has the potential to be available to help address the burden of RSV disease in the U.S. in time for the 2025-26 season

The FDA Has Accepted The Biologics License Application For Merck's Clesrovimab (MK-1654) To Protect Infants From Respiratory Syncytial Virus Disease During Their First Season, With Prescription Drug User Fee Act Or Target Action, Date Of June 10, 2025

Phase 3 KEYFORM-008 trial evaluated the fixed-dose combination of favezelimab and pembrolizumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL) whose disease has progressed following prior anti-PD-1 therapy.&nbsp;
Patients currently in this trial may continue on therapy until study completion. KEYFORM-008 is the only Phase 3 study in the KEYFORM clinical development program for which results are not available.&nbsp;
The company has made this decision after a thorough evaluation of data from the favezelimab clinical program and will prioritize the development of other candidates in its comprehensive and diversified oncology pipeline. This decision is not based on any concerns about the safety of this fixed-dose combination.

Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial

Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program.
&nbsp;
&nbsp;

Merck Reports Discontinuation Of Clinical Development Programs For Vibostolimab, An Anti-TIGIT Antibody, And Favezelimab, An Anti-LAG-3 Antibody

This approval marks the fourth non-small cell lung cancer (NSCLC) indication and the first indication in earlier stages of NSCLC for KEYTRUDA in China
 &nbsp;

The National Medical Products Administration In China Has Approved Merck's Keytruda In Combination With Platinum-containing Chemotherapy As Neoadjuvant Treatment And Then Continued As Monotherapy As Adjuvant Treatment After Surgery For Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Media

AMGN

EXEL

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

On Thursday, Bicycle Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) announced that it presented data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with&nbsp;NECTIN4 gene amplification at the 2024 San Antonio <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42475342/bicycle-therapeutics-announces-data-updates-across-zelenectide-pevedotin-program-and-development-s" rel="noreferrer noopener">Breast Conference Symposium</a>.
The company revealed topline combination data for zelenectide pevedotin plus Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC).
Topline results from the ongoing Phase 1/2 Duravelo-1 trial evaluating zelenectide pevedotin weekly plus pembrolizumab once every three weeks showed:
<ul>
<li>60% overall response rate (ORR) (12/20) among efficacy-evaluable patients. Of the responses, five were confirmed, and seven were unconfirmed at the time of the data cut. Fifteen patients remained on treatment at the time of the data cut.</li>
<li>The safety and tolerability profile was broadly consistent with late-line Duravelo-1 monotherapy and combination cohorts.</li>
<li>Adverse events of clinical interest, such as peripheral neuropathy, skin reactions, and eye disorders, were primarily low-grade.</li>
<li>There was one report of Grade 3 sensory peripheral neuropathy and one report of Grade 3 rash, both of which were transient and reverted to Grade 1 upon dose interruption.</li>
</ul>
Bicycle Therapeutics is currently conducting the Phase 2/3 Duravelo-2 trial evaluating zelenectide pevedotin plus pembrolizumab versus chemotherapy in first-line mUC (Cohort 1), and zelenectide pevedotin monotherapy and in combination with pembrolizumab in late-line mUC (Cohort 2).
Based on enrollment progress, the company plans to report dose selection and topline data for both cohorts in the second half of 2025.
The company also conducted a post-hoc analysis of 38 heavily pretreated breast cancer patients enrolled in Duravelo-1, of which 32 were confirmed to have triple-negative breast cancer (TNBC).
Of the 38 breast cancer patients enrolled, 35 patients were efficacy evaluable. Results showed:
<ul>
<li>62.5% ORR (5/8) among breast cancer patients with NECTIN4 gene amplification or polysomy, compared to 14.3% ORR (5/35) among all efficacy-evaluable breast cancer patients.</li>
<li>Of the 5 partial responses, 4 were confirmed and 1 was unconfirmed.</li>
<li>No responses in non-amplified or non-polysomy patients.</li>
</ul>
Of the 32 TNBC patients enrolled, 30 patients were efficacy evaluable. Additionally, 19 TNBC patient samples were available for&nbsp;NECTIN4 testing, of which 7 demonstrated NECTIN4 gene amplification or harbored a&nbsp;NECTIN4 polysomy. Results showed:
<ul>
<li>57.1% ORR (4/7) among TNBC patients with NECTIN4 gene amplification or polysomy, compared to 13.3% ORR (4/30) among all efficacy-evaluable TNBC patients.</li>
<li>Of the 4 partial responses, 3 were confirmed and 1 was unconfirmed.</li>
<li>All 3 TNBC patients with NECTIN4 gene amplification who responded to zelenectide pevedotin had prior treatment with sacituzumab govitecan.</li>
<li>No responses in non-amplified or non-polysomy patients.</li>
</ul>
The company conducted a post-hoc analysis of 40 pretreated patients with NSCLC with&nbsp;NECTIN4 Gene Amplification enrolled in Duravelo-1.
Of the 40 patients enrolled, 34 patients were efficacy evaluable. Additionally, 19 patient samples were available for&nbsp;NECTIN4 testing, of which 6 demonstrated&nbsp;NECTIN4 gene amplification. Results showed:
<ul>
<li>40.0% ORR (2/5) among patients with NECTIN4 gene amplification, compared to 8.8% ORR (3/34) among all efficacy-evaluable patients.</li>
<li>Of the 3 partial responses, 2 were confirmed and 1 was unconfirmed.</li>
<li>Out of 19 patients tested for NECTIN4 gene amplification, none of the non-amplified patients responded.</li>
</ul>
Price Action: BCYC stock is up 1.19% to $20.35 premarket at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42469927/google-has-the-ability-to-scale-ai-by-leveraging-its-global-user-base-analyst" target="_blank" rel="noreferrer noopener">Google Has The Ability To Scale AI By Leveraging Its Global User Base: Analyst</a></li>
</ul>

BCYC

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from...

Merck closes exclusive global license agreement for LM-299 from LaNova Medicines

BTIG raised the firm's price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares. The company's $50M investment from Mer...

Personalis price target raised to $8 from $7 at BTIG

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Nike downgraded, FedEx upgraded: Wall Street's top analyst calls

BTIG sees positive readthroughs to Viking Therapeutics (VKTX) after Novo Nordisk (NVO) reported 22.7% weight loss with weekly CagriSema from the 68...

BTIG reiterates Buy on Viking Therapeutics after Novo's CagriSema 'underwhelms'

Merck downgraded by BMO over Keytruda concerns

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: FedEx (FDX) reported lower-than-expect...

FedEx to separate Freight unit, Nike reports Q2 beat: Morning Buzz

If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy

Materials, software stocks are best poised for H1 outperformance: Goldman Sachs

SA Asks: Which Big Pharmas are likely to announce big M&A deals?

AAPL

AFRM

AKAM

APLD

ARDX

AVGO

BIIB

BKNG

CBRE

COST

CRSP

CRWD

CTSH

ENGN

ENVX

EOSE

EPAM

EQIX

EVRG

FICO

FREY

GOOG

GOOGL

HUMA

INCY

LQDA

LUMN

MRKR

MRNA

MSFT

NVDA

ORCL

PLTR

PODD

RDDT

RYTM

RZLV

SBUX

SCHL

TMUS

UTHR

VICI

VRTX

WELL

XLRE

XMTR

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

Merck's Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma

Merck's KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

Comments

Merck & Co

Noticias

Últimas noticias sobre Merck & Co (NYSE:MRK) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL